Lithium Tritertbutoxyaluminium Hydride Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is supplied as a selective reducing agent for pharmaceutical intermediates, not as a finished active pharmaceutical ingredient for direct administration. The compound is lithium tri-tert-butoxyaluminohydride, CAS 17476-04-9, molecular formula C12H28AlLiO3, molecular weight 254.28 g mol⁻¹. A representative pharma-grade supplier model designation is LTBAH-PG25 for the 25 kg nitrogen-inerted drum; pack sizes of 5 kg and 50 kg may be assigned separate lot-specific model codes. The material is a white-to-off-white powder with bulk density typically 0.45–0.65 g cm⁻³ by USP <616> Method I and particle size D90 ≤150 µm by laser diffraction according to ISO 13320. In pharmaceutical manufacturing, the reagent is used primarily for the controlled reduction of acid chlorides to aldehydes without over-reduction to primary alcohols. The resulting aldehyde intermediates are converted to APIs that can be formulated into tablets, capsules, granules, oral liquids, or injectable finished products.

Release specifications are supplier-specific because no pharmacopoeial monograph exists in USP, Ph. Eur., or JP. A typical pharma-grade certificate of analysis includes assay 98.0–102.0% by iodometric titration, water ≤0.2% by Karl Fischer titration according to USP <921> Method Ia, chloride ≤0.3%, and tetrahydrofuran-insoluble matter ≤0.1%. Residual tetrahydrofuran is controlled under ICH Q3C as a Class 2 solvent with a concentration limit of 720 ppm in the final API; injectable routes may require lower process-specific limits. Elemental impurities are controlled by ICP-MS with a risk assessment under ICH Q3D. Neither aluminium nor lithium is assigned a PDE in ICH Q3D, so release limits for these elements are derived from process-specific toxicological evaluation. The product is stored under nitrogen at 2–8 °C in tightly closed containers; unopened shelf-life is supplier-specified and typically 12 months from manufacture. Compared with technical-grade lithium tri-tert-butoxyaluminohydride, the pharma-grade material has a controlled impurity profile and supplier documentation suitable for active pharmaceutical ingredient manufacture.

Supplier qualification for pharma-grade use requires a quality agreement that includes residual solvent mapping under ICH Q3C, elemental impurity screening under ICH Q3D, and mutagenic impurity assessment under ICH M7. The manufacturer should provide a drug master file or technical package covering the synthetic route, critical process parameters, and storage stability. Because this reagent is a process reagent, not a finished API, it is released under IPEC GMP or ICH Q7 when the supplier is audited accordingly. Analytical method transfer follows USP <1225> for titrimetric and chromatographic procedures. Packaging uses double low-density polyethylene liners under nitrogen. Contact with water, alcohols, acids, acetone, and methyl ethyl ketone is incompatible because protic solvents hydrolyse the hydride and carbonyl-containing solvents may be reduced exothermically.

Reduction Selectivity and Interstage Isolation in API Synthesis

In a production-scale reduction, Lithium Tritertbutoxyaluminium Hydride Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is charged as a 20–30 wt% solution in anhydrous tetrahydrofuran to a glass-lined reactor that has been pre-dried with hot nitrogen at 80–100 °C for 60 min. The acid chloride substrate is dissolved in anhydrous tetrahydrofuran and held at −10 °C to 0 °C under a nitrogen blanket. The reagent addition is controlled so that the internal temperature does not exceed 5 °C; the molar ratio is maintained at 1.0–1.1 equivalents relative to the acid chloride. Addition above 1.15 equivalents increases the formation of the corresponding primary alcohol. In-process HPLC or GC-FID samples are taken every 10–15 min. The reaction is considered complete when the acid chloride peak area is ≤0.5% relative to the total aldehyde peak area.

The reaction mass is quenched at 0–5 °C with aqueous ammonium chloride or dilute sulfuric acid. The aqueous layer is separated at 25–30 °C, and the organic phase is extracted with methyl tert-butyl ether. The aldehyde intermediate is then isolated by vacuum distillation or crystallization from n-heptane or ethanol/water. Drying is performed in an agitated filter dryer under vacuum at 35–40 °C to a loss-on-drying value of ≤0.5% by USP <731>. The spent aqueous stream contains aluminium hydroxide and lithium salts, which are precipitated and removed as solid waste. The steric bulk of the three tert-butoxy ligands suppresses the formation of non-selective tetracoordinate aluminohydride species, but the selectivity window is maintained only while the reaction mass remains below 10 °C and the water content remains below 300 ppm. Field observations from production-scale batches show that moisture ingress during discharge is a recurring source of batch-to-batch over-reduction; therefore, charging lines are dried with anhydrous nitrogen before use. Published data for this specific configuration is limited; process parameters are verified during technology transfer using a process analytical technology scheme.

Hydrogen evolution during quench is a critical process safety parameter. The quench vessel is connected to a nitrogen-diluted vent with a lower explosive limit detector; the hydrogen/air mixture is maintained below 4 vol% by nitrogen flow. Quench addition rates are limited to 1–2 L min⁻¹ per 100 L reaction mass to prevent foam over and pressure surges. Reaction calorimetry is used to establish the maximum allowable quench rate for each campaign; published data for this specific configuration is limited.

Comparative performance against lithium aluminium hydride, sodium borohydride, and DIBAL-H is summarized below for temperature, selectivity, and metal-removal considerations in API synthesis. The principal difference is steric attenuation: three tert-butoxy ligands occupy coordination sites and reduce hydride nucleophilicity, allowing acid chloride reduction to stop at the aldehyde stage. Sodium borohydride is less moisture-sensitive but is generally insufficient for acid chloride-to-aldehyde conversion without additives. DIBAL-H requires cryogenic operation at −78 °C and generates aluminium gel workup issues. Lithium aluminium hydride reduces acid chlorides, esters, amides, and ketones non-selectively and is more difficult to control in multi-step API synthesis.

The reagent is selected when the synthetic route contains a reducible ester, nitrile, or ketone elsewhere in the molecule, because those groups remain largely intact under the controlled acid chloride reduction conditions. The selectivity margin narrows when the reactor temperature exceeds 10 °C or when the solvent water content exceeds 300 ppm; process deviations in either direction produce alcohol impurities that may require preparative chromatography or recrystallization to remove.

What Limits Residual Metal Carryover into Injectable Formulations?

Residual aluminium and lithium are the principal elemental impurities of concern when the final API is intended for injectable use. Neither element has an assigned PDE in ICH Q3D; therefore, marketing authorisation dossiers must justify control limits through non-clinical safety data or process capability. Aqueous workup and crystallization typically reduce residual aluminium to ≤10 ppm and lithium to ≤5 ppm in the final API, measured by ICP-MS according to USP <730> or Ph. Eur. 2.4.32. For injectable finished products, these limits may be tightened further because the product also must comply with USP <85> for bacterial endotoxins and USP <788> for particulate matter. The process reagent itself is not present in the finished injection; carryover is controlled at the API stage through washing, crystallization, and drying. Batch-to-batch variance in aluminium residue is influenced by the quench pH and the residence time of the aqueous layer; extended stirring at pH 8–9 promotes precipitation of aluminium hydroxide and reduces filter fouling on the agitated filter dryer.

Cleaning validation of reactors and drying equipment after campaigns uses swab and rinse sampling. Lithium and aluminium are measured by ICP-MS; acceptance limits are derived from the maximum allowable carryover of 10 ppm in the subsequent API. The reagent’s moisture sensitivity requires that equipment is dried before visual inspection and that cleaning operations are performed under nitrogen in the first rinse stage to prevent localized hydrolysis.

APIs synthesised with this reagent enter standard oral and parenteral formulation routes. For tablet and capsule intermediates, the isolated aldehyde or downstream alcohol is converted into the final API, then blended with excipients. In direct compression, the API particle size is controlled by milling to D90 ≤100 µm unless the formulation is a low-dose blend requiring micronization. For granules, wet granulation in a high-shear mixer with impeller speed 150–300 rpm and binder addition at 2–4% w/w is common; dry granulation by roller compaction is used for moisture-sensitive APIs. A twin-screw granulator with L/D ratio 25:1 can be used where continuous granulation is required, but it is not necessary for all APIs. Injectable presentations undergo dissolution, pH adjustment, filtration through 0.22 µm sterilizing membranes, and aseptic filling under EU GMP Annex 1 or ISO 13408-1. Tablets and capsules are tested for uniformity of dosage units according to USP <905> and dissolution according to USP <711>. The hydride reagent does not appear in the final dosage form; its influence is limited to residual solvents, elemental impurities, and potential aldehyde over-reduction impurities carried through the API.

When Moisture Ingress Exceeds 300 ppm During Dispensing

The critical handling boundary for this reagent is a moisture content above 300 ppm in the nitrogen blanket or in the reaction solvent. At that threshold, hydrolysis generates hydrogen gas and aluminium alkoxide species, reducing the available hydride content and shifting selectivity toward alcohol formation. Production-scale dispensing therefore occurs in an isolator or glovebag with a nitrogen atmosphere containing ≤10 ppm oxygen and ≤10 ppm water. Drum transfer is performed under positive nitrogen pressure; flexible connectors are purged with dry nitrogen for 15 min before product contact. The powder is charged through a rotary valve into a glass-lined or stainless steel reactor that has been pre-dried with hot nitrogen at 80–100 °C for 60 min. Solvent tetrahydrofuran is dried over 3A molecular sieves to a Karl Fischer value of ≤50 ppm water. If a batch exceeds the moisture threshold after charging, the selectivity loss is not correctable by adding more reagent; the batch is quenched and reworked. This failure mode is documented in production campaigns as a recurring source of batch-to-batch over-reduction and is mitigated by automated moisture sensors on transfer lines.